The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease
Open accessAbstract
Summary: Background: Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn's disease, even though some patients do not benefit from therapy. Aim: To assess the correlation between perianal fistula healing and trough levels of infliximab. Methods: In this cross‐sectional study, we identified patients with Crohn's disease who had perianal fistulas and were treated with infliximab for at least 24 weeks. We excluded patients who underwent a faecal diversion procedure or proctectomy. Predictive variables included demographics, disease phenotype, disease activity, infliximab levels, anti‐infliximab antibodies. The primary outcome was fistula healing defined as the absence of drainage. The secondary outcome was complete fistula closure and mucosal healing. Results: 117 patients were included. Patients with fistula healing had significantly higher median serum infliximab levels when compared to those with active fistulas [15.8 vs. 4.4 μg/mL, respectively ( P < 0.0001)]. There was an incremental gain in fistula healing with higher infliximab levels. The AUC for the association between fistula healing and infliximab levels was 0.82 ( P < 0.0001), while the AUC for the association of infliximab levels and fistula closure was 0.69 ( P = 0.014). Patients with anti‐infliximab antibodies had a lower chance of achieving fistula healing ( OR : 0.04 [95% CI : 0.005–0.3], P < 0.001). Conclusions: There is a significant association between serum infliximab levels and rates of fistula healing. Achieving infliximab levels ≥10.1 mcg/mL in patients with Crohn's disease and perianal fistulas may improve outcomes as part of a treat‐to‐target strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silverberg, M. S., Satsangi, J., Ahmad, T., Arnott, I. D., Bernstein, C. N., Brant, S. R., Caprilli, R., Colombel, J.-F., Gasche, C., Geboes, K., et al. (2005) · Canadian Journal of Gastroenterology · doi:10.1155/2005/269076 · Cited by 3,409
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota
Schwartz, D. A., Loftus, E. V., Tremaine, W. J., Panaccione, R., Harmsen, W. S., Zinsmeister, A. R., & Sandborn, W. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.32362 · Cited by 1,144
Maser, E. A., Villela, R., Silverberg, M. S., & Greenberg, G. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.025 · Cited by 613
Ungar, B., Levy, I., Yavne, Y., Yavzori, M., Picard, O., Fudim, E., Loebstein, R., Chowers, Y., Eliakim, R., Kopylov, U., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.10.025 · Cited by 370
Sandborn, W. J., Present, D. H., Isaacs, K. L., Wolf, D. C., Greenberg, E., Hanauer, S. B., Feagan, B. G., Mayer, L., Johnson, T., Galanko, J., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00877-1 · Cited by 333
Vande Casteele, N., Khanna, R., Levesque, B. G., Stitt, L., Zou, G. Y., Singh, S., Lockton, S., Hauenstein, S., Ohrmund, L., Greenberg, G. R., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307883 · Cited by 289
Yarur, A. J., Jain, A., Sussman, D. A., Barkin, J. S., Quintero, M. A., Princen, F., Kirkland, R., Deshpande, A. R., Singh, S., & Abreu, M. T. (2016) · Gut · doi:10.1136/gutjnl-2014-308099 · Cited by 242
Self-citation
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
ECCO guidelines on therapeutics in Crohn's disease: medical treatment
Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., Adamina, M., Armuzzi, A., Bachmann, O., Bager, P., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz180 · Cited by 1,374
Colombel, J.-F., D’haens, G., Lee, W.-J., Petersson, J., & Panaccione, R. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz131 · Cited by 283
Mitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., Begun, J., Bryant, R., Chan, W., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14368 · Cited by 282
Metadata
- Authors
- Yarur, A. J., Kanagala, V., Stein, D. J., Czul, F., Quintero, M. A., Agrawal, D., Patel, A., Best, K., Fox, C., Idstein, K., & Abreu, M. T.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-02-17
- Volume
- 45
- Issue
- 7
- Pages
- 933-940
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2587787178
- Cited by
- 308
- References
- 16
- FWCI
- 22.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. https://app.cochat.ai/papers/10.1111/apt.13970
- The paper
- Yarur, A. J., Kanagala, V., Stein, D. J., Czul, F., Quintero, M. A., Agrawal, D., Patel, A., Best, K., Fox, C., Idstein, K., & Abreu, M. T. (2017). Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.13970
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
